The HeartFlow FFRCT Analysis is the first non-invasive diagnostic tool that aids clinicians in determining, vessel by vessel, both the extent of an artery’s narrowing and the impact that the narrowing has on blood flow to the heart.
Find your nearest AHSN
Heartflow is able to non-invasively identify which patients do and do not need intervention, clinicians can reduce unnecessary invasive testing, reduce healthcare system costs and improve patient quality of life. The solution has the capacity to transform the way coronary artery disease is diagnosed and treated.
With the support of the West Midlands Academic Health Science Network (WMAHSN), Russells Hall Hospital became one of the first hospitals to make HeartFlow available to patients. Other Trusts in the region are in advanced discussions with HeartFlow and are likely to start using HeartFlow in the near future.
How did the Innovation Exchange help?
The WMAHSN engaged with HeartFlow via the Meridian Innovation Health Exchange and invited the company to the launch event for the NHS Innovation and Technology Payment (ITP) programme while assisting the company to engage with the region’s NHS Trusts via their Membership Innovation Councils (MICs). The AHSN also supported them through the ITP application process and Heartflow is now one of four successful ITP innovations being rolled out nationally.
With increasing interest from hospital Trusts and funding from NHS England through the ITP programme, HeartFlow has begun to expand their UK presence, growing their commercial team including local experts in technology, information governance, economics, and commercial development.
Impact & Outcomes
A clinical utility study, PLATFORM, including hospital Trusts in England, looked at the clinical and economic impact of HeartFlow. Incorporating HeartFlow into clinical care resulted in an 83% reduction in angiographies for patients without obstructive disease and a 26% reduction in costs of care. Patients where the invasive angiography was cancelled were followed for 12 months and there were no adverse events. Patients without disease were able to return home safely, while those in need of care were accurately identified and treated.
Today there are over 2 million patients in the UK with coronary heart disease. (British Heart Foundation, CVD Statistics, 2018). While HeartFlow is still at an early stage, as adoption increases, the potential benefits are significant. As NICE chest pain guidelines are adopted and access to non-invasive CCTA (coronary CT angiogram) increases, cost savings could continue to expand beyond NICE estimates.